New HIV drug lipovirtide tested for safety in early trial
NCT ID NCT04592315
First seen Apr 20, 2026 · Last updated May 19, 2026 · Updated 6 times
Summary
This early-stage study tested a single injection of a new drug, lipovirtide, in 46 HIV-positive adults who had never taken antiviral medication. The main goal was to see if the drug is safe and how the body processes it. This is a first step in developing a potential new treatment for HIV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing You'an Hospital, Beijing Medical University
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.